Pathologic and molecular responses to neoadjuvant trastuzumab and/or lapatinib from a phase II randomized trial in HER2-positive breast cancer (TRIO-US B07)

In this multicenter, open-label, randomized phase II investigator-sponsored neoadjuvant trial with funding provided by Sanofi and GlaxoSmithKline (TRIO-US B07, Clinical Trials NCT00769470), participants with early-stage HER2-positive breast cancer (N = 128) were recruited from 13 United States oncol...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Nat Commun
Prif Awduron: Hurvitz, Sara A., Caswell-Jin, Jennifer L., McNamara, Katherine L., Zoeller, Jason J., Bean, Gregory R., Dichmann, Robert, Perez, Alejandra, Patel, Ravindranath, Zehngebot, Lee, Allen, Heather, Bosserman, Linda, DiCarlo, Brian, Kennedy, April, Giuliano, Armando, Calfa, Carmen, Molthrop, David, Mani, Aruna, Chen, Hsiao-Wang, Dering, Judy, Adams, Brad, Kotler, Eran, Press, Michael F., Brugge, Joan S., Curtis, Christina, Slamon, Dennis J.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Nature Publishing Group UK 2020
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC7673127/
https://ncbi.nlm.nih.gov/pubmed/33203854
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41467-020-19494-2
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg